The clinical status and working capacity in patients included in the All-Russian Psoriatic Arthritis Registry

Objective: to study the clinical characteristics of PsA and working capacity in patients included in the All-Russian PsA Registry.

Patients and methods. The investigation enrolled 614 patients aged 19–84 years with psoriasis from 39 subjects the Russian Federation, who were followed up in the All-Russian PsA Registry. On the basis of the assessment of demographic data, the spectrum of comorbidities, the degree of activity of the underlying disease according to Disease Activity Index for PsA (DAPSA) and Disease Activity in 28 joints (DAS28), clinical, functional, and social indicators were analyzed in the patients. The investigators studied information on the patients employment, working capacity, and disability, by assessing the group of the latter. The health status and the presence and severity of functional impairment in the patients were analyzed using the Health Assessment Questionnaire (HAQ), while their working efficiency was estimated according to the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP questionnaire), by calculating the following parameters: absenteeism, presenteeism, an overall decrease in labor productivity, and impairment in daily functional activity.

Results and discussion. The analysis of the All-Russian PsA Registry showed that most of them were of working age (30 to 59 years); 48.4% had concomitant diseases. Data on DAPSA changes were obtained in 349 patients, who were recorded to have mainly moderate (34.7%) or high (42.7%) disease activity, multiple dactylitides and enthesitides, and limited joint function. The registry reflects information on the social status of 521 patients: employed (61.2%) and unemployed (22.1%) persons, pensioners (15.2%), and students (1.5%). More than one third (37.1%) of patients with PsA had disability, mainly of Group III. The changes in the HAQ disability index were assessed in 326 patients; mild, moderate, and severe functional impairments were observed in 36, 26.4, and 3.7%, respectively. Absenteeism was detected in less than one third of patients with PsA, presenteeism was found in about half; there was an overall decrease in labor productivity in more than 60% and daily activity impairment in 68.8%. Statistically significant direct moderate correlations were established between the indicators of PsA activity (DAPSA and DAS28) and the level of productivity impairment in the patients; this was mostly related to an overall decline in labor productivity and to a decrease in daily activity.

Conclusion. The data obtained from real clinical practice suggest that half of the PsA patients had high disease activity and a third had severe functional impairment, which led to a lower quality of life and to disability. The overall decrease in labor productivity and daily activity, which was detected in more than half of the patients, was associated with high PsA activity. The follow-up in the All-Russian PsA Registry, regular anti-inflammatory therapy with disease-modifying antirheumatic drugs and biological agents can improve the clinical and functional status and, consequently, working capacity in patients with PsA.

1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017 Mar 9; 376(10):957-70. doi: 10.1056/NEJMra1505557.

2. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 2; 391(10136):2273-84. doi: 10.1016/S01406736(18)30830-4. Epub 2018 Jun 1.

3. Korotaeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1):60-9. (In Russ.). doi: 10.14412/1995-4484-2018-1-60-69.

4. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009 Jul;68(7):1131-5. doi: 10.1136/ard.2008.094839.

5. Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Apr;66(4):600-7. doi: 10.1002/acr.22185.

6. Tillett W, Shaddick G, Askari A, et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology (Oxford). 2015 Jan;54(1):157-62. doi: 10.1093/rheumatology/keu264. Epub 2014 Aug 13.

7. Zhang W, Bansback N, Boonen A, et al. Validity of the work productivity and activity impairment questionnaire – general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177. doi: 10.1186/ar3141. Epub 2010 Sep 22.

8. Vakulenko OYu, Goryachev DV, Krichevskaya OA, Erdes ShF. Evaluation of a decrese in work productivity in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):671–9. (In Russ.). doi: 10.14412/1995-4484-2013-6.

9. Tillett W, de Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford). 2012 Feb; 51(2):275-83. doi: 10.1093/rheumatology/ker216. Epub 2011 Jul 13.

10. Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology (Oxford). 2012 Feb;51(2):210-5. doi: 10.1093/rheumatology/ker348.

11. Fries JF, Picnic T, Wolfe F. Usefulness of the HAQ in the clinic. Ann Rheum Dis. 2001 Aug;60(8):811. doi: 10.1136/ard.60.8.811.

12. Erdes ShF, Folomeeva OM, Galushko EA, Tel'nykh MYu. Results of cross-sectional epidemiologic study on determination of recombinant biological agents requirement for treatment of patients with rheumatoid arthritis in real-life clinical practice. Report 1. Demographic, social, clinicaland laboratory characteristics of Russian patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(6):4-13. (In Russ.). doi: 10.14412/1995-4484-2009-6

13. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993 Nov;4(5): 353-65. doi: 10.2165/00019053199304050-00006.

14. Merola JF, Shrom D, Eaton J, et al. Patient perspective on the durden of skin and joint symptoms of psoriatic arthritis: results of a Multi-National patient survey. Rheumatol Ther. 2019 Mar;6(1):33-45. doi: 10.1007/s40744-018-0135-1. Epub 2019 Jan 4.

15. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010 Dec;35(12):680-9.

16. Mease PJ, Liu M, Rebello S, et al. Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries. Rheumatol Ther. 2019 Dec;6(4):529-42. doi: 10.1007/s40744-019-00172-9. Epub 2019 Sep 16.

17. Korotaeva TV, Korsakova YuL, Loginova EYu, et al. Optimizing the diagnosis, a monitoring and treatment system for psoriatic arthritis in real practice: general principles for organizing an all-russian register of patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(4):407-14. (In Russ.). doi: 10.14412/1995-4484-2019-407-414.

18. Helliwell PS, Ruderman E. Natural history, prognosis, and Socioeconomic aspects of psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):581-91. doi: 10.1016/j.rdc.2015.07.004. Epub 2015 Aug 24.

19. Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010 Mar; 62(3):345-53. doi: 10.1002/acr.20104.

20. Verstappen SM, Watson KD, Lunt M, et al. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2010 Aug;49(8):1570-7. doi: 10.1093/rheumatology/keq131. Epub 2010 May 5.

21. Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2015 Jan;74(1):44-51. doi: 10.1136/annrheumdis-2014-205198. Epub 2014 Jun 18.

22. Coates L, Orbai A, Morita A, et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity. BMC Rheumatol. 2018 Aug 13; 2:24. doi: 10.1186/s41927-018-0030-y. eCollection 2018.